Athira’s alternative Alzheimer’s approach runs into a PhII brick wall
Athira Pharma reported another setback Wednesday as its mid-stage Alzheimer’s study failed, becoming the latest biotech to come up short in the disease.
The Seattle-area company said the Phase II trial comparing its lead candidate fosgonimeton, formerly ATH-1017, against placebo did not achieve its primary endpoint nor a litany of secondary measures. It’s yet another challenge for Athira following revelations its former CEO doctored some of the company’s foundational research in grad school and activist investor campaigns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.